SlideShare a Scribd company logo
Biochempeg https://www.biochempeg.com
Large-Scale Monodisperse PEG Products
Biochempeg continuously expands its capability to provide large-scale manufacture of
high purity monodisperse PEG derivatives with an extensive variety of functional groups,
in both non-GMP and GMP grade.
Monodisperse PEG retains the good water solubility of polyethylene glycol, and provides
the same PEG benefits for PEGylated drugs, namely reducing aggregation and
immunogenicity, and increasing hydrodynamic volume.
The following are some examples of our monodisperse PEG products with
purity >95% that have been scaled up to kilogram scale batch size.
No. Cat.No Cas No. Name
1 MD003003-3 2781-02-4 SH-PEG3-SH
Biochempeg https://www.biochempeg.com
2 MD002002-9 3386-18-3 OH-PEG9-OH
3 MD002002-8 5117-19-1 OH-PEG8-OH
4 MD002016-6 1347750-85-9 OH-PEG6-COOH
5 MD002016-4 937188-59-5 OH-PEG4-COOH
6 MD002002-12 6790-09-6 OH-PEG12-OH
7 MD006300-8 846549-37-9 O-(2-AZIDOETHYL)-O-(2-(DIGLYCOLYL-AMINO)ETHYL)EG-7
8 MD005002-8 352439-37-3 NH2-PEG8-OH
9 MD005005-8 82209-36-7 NH2-PEG8-NH2
10 MD005002-7 1425973-14-3 NH2-PEG7-OH
11 MD005016-6 905954-28-1 NH2-PEG6-COOH
12 MD005121-5 141282-35-1 NH2-PEG5-CH2COOH
13 MD005067-5 1446282-18-3 NH2-PEG5-CH2CH2COOtBu
14 MD005128-4 864680-64-8 NH2-PEG4-CH2COOtBu
15 MD005067-4 581065-95-4 NH2-PEG4-CH2CH2COOtBu
16 MD005002-3 6338-55-2 NH2-PEG3-OH
17 MD005128-3 189808-70-6 NH2-PEG3-CH2COOtBu
18 MD005067-3 252881-74-6 NH2-PEG3-CH2CH2COOtBu
19 MD000018-36 NH2-PEG36-CONH-PEG36-COOH
20 MD005067-2 756525-95-8 NH2-PEG2-CH2CH2COOtBu
21 MD005016-24 NH2-PEG24-COOH
22 MD000016-3 1814901-04-6 NH-(PEG3-Acid)2
23 MD006016-9 1670249-37-2 N3-PEG9-COOH
24 MD006067-9 N3-PEG9-CH2CH2COOtBu
25 MD006002-8 352439-36-2 N3-PEG8-OH
26 MD006005-8 857891-82-8 N3-PEG8-NH2
27 MD006016-8 1214319-92-2 N3-PEG8-COOH
28 MD006121-8 1343472-07-0 N3-PEG8-CH2COOH
29 MD006067-8 1623791-99-0 N3-PEG8-CH2CH2COOtBu
30 MD006002-6 86770-69-6 N3-PEG6-OH
31 MD006016-6 361189-66-4 N3-PEG6-COOH
32 MD006128-6 297162-49-3 N3-PEG6-CH2COOtBu
33 MD006121-6 N3-PEG6-CH2COOH
34 MD006067-6 406213-76-1 N3-PEG6-CH2CH2COOtBu
35 MD006016-5 1425973-16-5 N3-PEG5-COOH
36 MD006128-5 1448451-72-6 N3-PEG5-CH2COOtBu
37 MD006121-5 N3-PEG5-CH2COOH
38 MD006067-5 1415800-41-7 N3-PEG5-CH2CH2COOtBu
39 MD006016-4 1257063-35-6 N3-PEG4-COOH
40 MD006128-4 N3-PEG4-CH2COOtBu
41 MD006121-4 201467-81-4 N3-PEG4-CH2COOH
42 MD006067-4 581066-04-8 N3-PEG4-CH2CH2COOtBu
Biochempeg https://www.biochempeg.com
43 MD006025-3 N3-PEG3-SPA
44 MD006121-3 172531-37-2 N3-PEG3-CH2COOH
45 MD006067-3 252881-73-5 N3-PEG3-CH2CH2COOtBu
46 MD006016-2 1312309-63-9 N3-PEG2-COOH
47 MD006128-2 251564-45-1 N3-PEG2-CH2COOtBu
48 MD006121-2 882518-90-3 N3-PEG2-CH2COOH
49 MD006067-2 1271728-79-0 N3-PEG2-CH2CH2COOtBu
50 MD006002-12 N3-PEG12-OH
51 MD006016-12 1167575-20-3 N3-PEG12-COOH
52 MD006005-10 912849-73-1 N3-PEG10-NH2
53 MD006016-10 1644163-57-4 N3-PEG10-COOH
54 QT300006-3 2182602-17-9 N-(ACID-PEG3)-N-BIS(PEG3-Azide)
55 MD000017-3 2183440-35-7 N-(ACID-PEG3)-N-BIS(PEG3-AMINE)
56 MD001002-9 6048-68-6 mPEG9-OH
57 MD001005-7 170572-38-0 mPEG7-NH2
58 MD001056-7 104518-25-4 mPEG7-Br
59 MD001005-36 32130-27-1 mPEG36-NH2
60 MD001005-24 2151823-08-2 mPEG24-NH2
61 MD001025-11 756525-94-7 mPEG11-SPA
62 MD069016-8 756526-02-0 Fmoc-NH-PEG8-COOH
63 MD069121-8 868594-52-9 Fmoc-NH-PEG8-CH2COOH
64 MD069016-6 882847-34-9 Fmoc-NH-PEG6-COOH
65 MD069016-5 882847-32-7 Fmoc-NH-PEG5-COOH
66 MD069121-5 635287-26-2 Fmoc-NH-PEG5-CH2COOH
67 MD069002-4 Fmoc-NH-PEG4-OH
68 MD069005-4 FMOC-NH-PEG4-NH2
69 MD069016-4 557756-85-1 Fmoc-NH-PEG4-COOH
70 MD069121-4 437655-95-3 Fmoc-NH-PEG4-CH2COOH
71 MD069121-3 139338-72-0 Fmoc-NH-PEG3-CH2COOH
72 MD069016-36 850312-72-0 Fmoc-NH-PEG36-COOH
73 MD069016-1 1654740-73-4 Fmoc-NH-PEG1-COOH
74 MD069016-12 756526-01-9 Fmoc-NH-PEG12-COOH
75 MD016050-24 COOH-PEG24-NH2.HCl
76 MD068002-6 331242-61-6 Boc-NH-PEG6-OH
77 MD068005-6 1091627-77-8 BOC-NH-PEG6-NH2
78 MD068016-6 882847-13-4 Boc-NH-PEG6-COOH
79 MD068002-5 1404111-67-6 Boc-NH-PEG5-OH
80 MD068005-5 189209-27-6 BOC-NH-PEG5-NH2
81 MD068016-5 1347750-78-0 Boc-NH-PEG5-COOH
82 MD068002-4 106984-09-2 Boc-NH-PEG4-OH
Biochempeg https://www.biochempeg.com
83 MD068005-4 811442-84-9 BOC-NH-PEG4-NH2
84 MD068016-4 756525-91-4 Boc-NH-PEG4-COOH
85 MD068122-4 Boc-NH-PEG4-CH2CH2-tBul
86 MD068137-4 1416777-48-4 Boc-NH-PEG4-CH2CH2CH2COOH
87 MD068002-3 139115-92-7 Boc-NH-PEG3-OH
88 MD068005-3 101187-40-0 BOC-NH-PEG3-NH2
89 MD068016-3 1347750-75-7 Boc-NH-PEG3-COOH
90 MD068121-3 462100-06-7 Boc-NH-PEG3-CH2COOH
91 MD068002-2 139115-91-6 Boc-NH-PEG2-OH
92 MD068068-2 475591-59-4 Boc-NH-PEG2-NH-Boc
93 MD068005-2 153086-78-3 BOC-NH-PEG2-NH2
94 MD068016-2 1365655-91-9 Boc-NH-PEG2-COOH
95 MD068121-2 108466-89-3 Boc-NH-PEG2-CH2COOH
96 MD068005-1 127828-22-2 BOC-NH-PEG1-NH2
97 MD007002-7 1422023-54-8 Alkyne-PEG7-OH
98 MD007002-6 944560-99-0 Alkyne-PEG6-OH
99 MD007002-5 1036204-60-0 Alkyne-PEG5-OH
100 MD007002-4 87450-10-0 Alkyne-PEG4-OH
101 MD007002-3 208827-90-1 Alkyne-PEG3-OH
102 MD007002-2 7218-43-1 Alkyne-PEG2-OH

More Related Content

More from DoriaFang

Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
DoriaFang
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
DoriaFang
 

More from DoriaFang (20)

Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdfNectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
Nectin-4 New Antibody-Drug Conjugate (ADC) Target.pdf
 
PROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdfPROTAC Delivery System Recent Research Advances.pdf
PROTAC Delivery System Recent Research Advances.pdf
 

Recently uploaded

Creative Web Design Company in Singapore
Creative Web Design Company in SingaporeCreative Web Design Company in Singapore
Creative Web Design Company in Singapore
techboxsqauremedia
 
Structural Design Process: Step-by-Step Guide for Buildings
Structural Design Process: Step-by-Step Guide for BuildingsStructural Design Process: Step-by-Step Guide for Buildings
Structural Design Process: Step-by-Step Guide for Buildings
Chandresh Chudasama
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
FelixPerez547899
 
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel ChartSatta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesEvent Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Holger Mueller
 
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
my Pandit
 
Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership Agile Tour Geneve 2024Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership Agile Tour Geneve 2024
Kirill Klimov
 
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
my Pandit
 
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
APCO
 
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
Aleksey Savkin
 
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Neil Horowitz
 
Industrial Tech SW: Category Renewal and Creation
Industrial Tech SW:  Category Renewal and CreationIndustrial Tech SW:  Category Renewal and Creation
Industrial Tech SW: Category Renewal and Creation
Christian Dahlen
 
Innovation Management Frameworks: Your Guide to Creativity & Innovation
Innovation Management Frameworks: Your Guide to Creativity & InnovationInnovation Management Frameworks: Your Guide to Creativity & Innovation
Innovation Management Frameworks: Your Guide to Creativity & Innovation
Operational Excellence Consulting
 
Building Your Employer Brand with Social Media
Building Your Employer Brand with Social MediaBuilding Your Employer Brand with Social Media
Building Your Employer Brand with Social Media
LuanWise
 
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
Lacey Max
 
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
AnnySerafinaLove
 
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your TasteZodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
my Pandit
 
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
 
-- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month ---- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month --
NZSG
 
Best practices for project execution and delivery
Best practices for project execution and deliveryBest practices for project execution and delivery
Best practices for project execution and delivery
CLIVE MINCHIN
 

Recently uploaded (20)

Creative Web Design Company in Singapore
Creative Web Design Company in SingaporeCreative Web Design Company in Singapore
Creative Web Design Company in Singapore
 
Structural Design Process: Step-by-Step Guide for Buildings
Structural Design Process: Step-by-Step Guide for BuildingsStructural Design Process: Step-by-Step Guide for Buildings
Structural Design Process: Step-by-Step Guide for Buildings
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
 
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel ChartSatta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
 
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesEvent Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challenges
 
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...
 
Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership Agile Tour Geneve 2024Organizational Change Leadership Agile Tour Geneve 2024
Organizational Change Leadership Agile Tour Geneve 2024
 
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...
 
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...
 
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...
 
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
 
Industrial Tech SW: Category Renewal and Creation
Industrial Tech SW:  Category Renewal and CreationIndustrial Tech SW:  Category Renewal and Creation
Industrial Tech SW: Category Renewal and Creation
 
Innovation Management Frameworks: Your Guide to Creativity & Innovation
Innovation Management Frameworks: Your Guide to Creativity & InnovationInnovation Management Frameworks: Your Guide to Creativity & Innovation
Innovation Management Frameworks: Your Guide to Creativity & Innovation
 
Building Your Employer Brand with Social Media
Building Your Employer Brand with Social MediaBuilding Your Employer Brand with Social Media
Building Your Employer Brand with Social Media
 
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
How are Lilac French Bulldogs Beauty Charming the World and Capturing Hearts....
 
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.
 
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your TasteZodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
 
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta MatkaDpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
 
-- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month ---- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month --
 
Best practices for project execution and delivery
Best practices for project execution and deliveryBest practices for project execution and delivery
Best practices for project execution and delivery
 

Large scale monodisperse peg products

  • 1. Biochempeg https://www.biochempeg.com Large-Scale Monodisperse PEG Products Biochempeg continuously expands its capability to provide large-scale manufacture of high purity monodisperse PEG derivatives with an extensive variety of functional groups, in both non-GMP and GMP grade. Monodisperse PEG retains the good water solubility of polyethylene glycol, and provides the same PEG benefits for PEGylated drugs, namely reducing aggregation and immunogenicity, and increasing hydrodynamic volume. The following are some examples of our monodisperse PEG products with purity >95% that have been scaled up to kilogram scale batch size. No. Cat.No Cas No. Name 1 MD003003-3 2781-02-4 SH-PEG3-SH
  • 2. Biochempeg https://www.biochempeg.com 2 MD002002-9 3386-18-3 OH-PEG9-OH 3 MD002002-8 5117-19-1 OH-PEG8-OH 4 MD002016-6 1347750-85-9 OH-PEG6-COOH 5 MD002016-4 937188-59-5 OH-PEG4-COOH 6 MD002002-12 6790-09-6 OH-PEG12-OH 7 MD006300-8 846549-37-9 O-(2-AZIDOETHYL)-O-(2-(DIGLYCOLYL-AMINO)ETHYL)EG-7 8 MD005002-8 352439-37-3 NH2-PEG8-OH 9 MD005005-8 82209-36-7 NH2-PEG8-NH2 10 MD005002-7 1425973-14-3 NH2-PEG7-OH 11 MD005016-6 905954-28-1 NH2-PEG6-COOH 12 MD005121-5 141282-35-1 NH2-PEG5-CH2COOH 13 MD005067-5 1446282-18-3 NH2-PEG5-CH2CH2COOtBu 14 MD005128-4 864680-64-8 NH2-PEG4-CH2COOtBu 15 MD005067-4 581065-95-4 NH2-PEG4-CH2CH2COOtBu 16 MD005002-3 6338-55-2 NH2-PEG3-OH 17 MD005128-3 189808-70-6 NH2-PEG3-CH2COOtBu 18 MD005067-3 252881-74-6 NH2-PEG3-CH2CH2COOtBu 19 MD000018-36 NH2-PEG36-CONH-PEG36-COOH 20 MD005067-2 756525-95-8 NH2-PEG2-CH2CH2COOtBu 21 MD005016-24 NH2-PEG24-COOH 22 MD000016-3 1814901-04-6 NH-(PEG3-Acid)2 23 MD006016-9 1670249-37-2 N3-PEG9-COOH 24 MD006067-9 N3-PEG9-CH2CH2COOtBu 25 MD006002-8 352439-36-2 N3-PEG8-OH 26 MD006005-8 857891-82-8 N3-PEG8-NH2 27 MD006016-8 1214319-92-2 N3-PEG8-COOH 28 MD006121-8 1343472-07-0 N3-PEG8-CH2COOH 29 MD006067-8 1623791-99-0 N3-PEG8-CH2CH2COOtBu 30 MD006002-6 86770-69-6 N3-PEG6-OH 31 MD006016-6 361189-66-4 N3-PEG6-COOH 32 MD006128-6 297162-49-3 N3-PEG6-CH2COOtBu 33 MD006121-6 N3-PEG6-CH2COOH 34 MD006067-6 406213-76-1 N3-PEG6-CH2CH2COOtBu 35 MD006016-5 1425973-16-5 N3-PEG5-COOH 36 MD006128-5 1448451-72-6 N3-PEG5-CH2COOtBu 37 MD006121-5 N3-PEG5-CH2COOH 38 MD006067-5 1415800-41-7 N3-PEG5-CH2CH2COOtBu 39 MD006016-4 1257063-35-6 N3-PEG4-COOH 40 MD006128-4 N3-PEG4-CH2COOtBu 41 MD006121-4 201467-81-4 N3-PEG4-CH2COOH 42 MD006067-4 581066-04-8 N3-PEG4-CH2CH2COOtBu
  • 3. Biochempeg https://www.biochempeg.com 43 MD006025-3 N3-PEG3-SPA 44 MD006121-3 172531-37-2 N3-PEG3-CH2COOH 45 MD006067-3 252881-73-5 N3-PEG3-CH2CH2COOtBu 46 MD006016-2 1312309-63-9 N3-PEG2-COOH 47 MD006128-2 251564-45-1 N3-PEG2-CH2COOtBu 48 MD006121-2 882518-90-3 N3-PEG2-CH2COOH 49 MD006067-2 1271728-79-0 N3-PEG2-CH2CH2COOtBu 50 MD006002-12 N3-PEG12-OH 51 MD006016-12 1167575-20-3 N3-PEG12-COOH 52 MD006005-10 912849-73-1 N3-PEG10-NH2 53 MD006016-10 1644163-57-4 N3-PEG10-COOH 54 QT300006-3 2182602-17-9 N-(ACID-PEG3)-N-BIS(PEG3-Azide) 55 MD000017-3 2183440-35-7 N-(ACID-PEG3)-N-BIS(PEG3-AMINE) 56 MD001002-9 6048-68-6 mPEG9-OH 57 MD001005-7 170572-38-0 mPEG7-NH2 58 MD001056-7 104518-25-4 mPEG7-Br 59 MD001005-36 32130-27-1 mPEG36-NH2 60 MD001005-24 2151823-08-2 mPEG24-NH2 61 MD001025-11 756525-94-7 mPEG11-SPA 62 MD069016-8 756526-02-0 Fmoc-NH-PEG8-COOH 63 MD069121-8 868594-52-9 Fmoc-NH-PEG8-CH2COOH 64 MD069016-6 882847-34-9 Fmoc-NH-PEG6-COOH 65 MD069016-5 882847-32-7 Fmoc-NH-PEG5-COOH 66 MD069121-5 635287-26-2 Fmoc-NH-PEG5-CH2COOH 67 MD069002-4 Fmoc-NH-PEG4-OH 68 MD069005-4 FMOC-NH-PEG4-NH2 69 MD069016-4 557756-85-1 Fmoc-NH-PEG4-COOH 70 MD069121-4 437655-95-3 Fmoc-NH-PEG4-CH2COOH 71 MD069121-3 139338-72-0 Fmoc-NH-PEG3-CH2COOH 72 MD069016-36 850312-72-0 Fmoc-NH-PEG36-COOH 73 MD069016-1 1654740-73-4 Fmoc-NH-PEG1-COOH 74 MD069016-12 756526-01-9 Fmoc-NH-PEG12-COOH 75 MD016050-24 COOH-PEG24-NH2.HCl 76 MD068002-6 331242-61-6 Boc-NH-PEG6-OH 77 MD068005-6 1091627-77-8 BOC-NH-PEG6-NH2 78 MD068016-6 882847-13-4 Boc-NH-PEG6-COOH 79 MD068002-5 1404111-67-6 Boc-NH-PEG5-OH 80 MD068005-5 189209-27-6 BOC-NH-PEG5-NH2 81 MD068016-5 1347750-78-0 Boc-NH-PEG5-COOH 82 MD068002-4 106984-09-2 Boc-NH-PEG4-OH
  • 4. Biochempeg https://www.biochempeg.com 83 MD068005-4 811442-84-9 BOC-NH-PEG4-NH2 84 MD068016-4 756525-91-4 Boc-NH-PEG4-COOH 85 MD068122-4 Boc-NH-PEG4-CH2CH2-tBul 86 MD068137-4 1416777-48-4 Boc-NH-PEG4-CH2CH2CH2COOH 87 MD068002-3 139115-92-7 Boc-NH-PEG3-OH 88 MD068005-3 101187-40-0 BOC-NH-PEG3-NH2 89 MD068016-3 1347750-75-7 Boc-NH-PEG3-COOH 90 MD068121-3 462100-06-7 Boc-NH-PEG3-CH2COOH 91 MD068002-2 139115-91-6 Boc-NH-PEG2-OH 92 MD068068-2 475591-59-4 Boc-NH-PEG2-NH-Boc 93 MD068005-2 153086-78-3 BOC-NH-PEG2-NH2 94 MD068016-2 1365655-91-9 Boc-NH-PEG2-COOH 95 MD068121-2 108466-89-3 Boc-NH-PEG2-CH2COOH 96 MD068005-1 127828-22-2 BOC-NH-PEG1-NH2 97 MD007002-7 1422023-54-8 Alkyne-PEG7-OH 98 MD007002-6 944560-99-0 Alkyne-PEG6-OH 99 MD007002-5 1036204-60-0 Alkyne-PEG5-OH 100 MD007002-4 87450-10-0 Alkyne-PEG4-OH 101 MD007002-3 208827-90-1 Alkyne-PEG3-OH 102 MD007002-2 7218-43-1 Alkyne-PEG2-OH